Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation

@inproceedings{Leo2014AcuteII,
  title={Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation},
  author={Chen H Leo and Maria Jelinic and Helena C Parkington and Marianne Tare and Laura J Parry},
  booktitle={Journal of the American Heart Association},
  year={2014}
}
BACKGROUND A recent clinical trial (RELAXin in Acute Heart Failure [RELAX-AHF]) demonstrated that 48 hours of continuous intravenous infusion of the vasorelaxant peptide serelaxin (recombinant human relaxin-2) to patients with acute heart failure reduced cardiovascular mortality at 180 days. The persistence of a vasorelaxant response as a potential mechanism for this long-term benefit and the vascular effects of a bolus intravenous injection of serelaxin have not been examined. This study… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
19 Citations
51 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Decreased uterine and mesenteric artery compliance in pregnant mutant mice

  • JH Gooi, M Richardson, +4 authors LJ. Parry
  • Reprod Sci
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…